Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01310530 · ClinicalTrials.gov registry record · NA
Partial Breast Proton Therapy for Early Stage Breast Cancer
A NA study of Breast Cancer, sponsored by Loma Linda University.
- Active
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT01310530: Active NA study of Breast Cancer, sponsored by Loma Linda University.
NCT01310530 is a NA study of Breast Cancer that is active but no longer recruiting, run by Loma Linda University. The registered enrollment target is 150 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01310530, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Loma Linda University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this is to determine the efficacy and toxicity of proton therapy when used to deliver partial breast radiotherapy in patients with early stage breast cancer with low or intermediate risk factors.
Conditions Studied
Interventions
- RADIATION Proton Beam Radiotherapy
Study Locations (2)
California
- Loma Linda University Medical Center / James M. Slater MD Proton Treatment Center / Department of Radiation Medicine / 11234 Anderson St. - Loma Linda
- Loma Linda University Medical Center - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2011-05-04 |
| Est. Completion | 2026-12 |
| Phase | NA |
What the registry record for NCT01310530 still lists
NCT01310530 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Proton Beam Radiotherapy is the first listed.
NCT01310530 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01310530 about?
NCT01310530 is a clinical study titled "Partial Breast Proton Therapy for Early Stage Breast Cancer". The purpose of this is to determine the efficacy and toxicity of proton therapy when used to deliver partial breast radiotherapy in patients with early stage breast cancer with low or intermediate risk factors.
What is the current status of trial NCT01310530?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2011-05-04. Estimated completion is 2026-12.
What conditions does trial NCT01310530 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01310530?
The interventions under investigation include: Proton Beam Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT01310530?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01310530 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01310530's enrollment target sits among peer trials
150 444th of 1224 higher than 772 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI